Complicated coronavirus disease 2019 (COVID-19) in a psoriatic patient treated with ixekizumab

被引：11

作者：

Facheris, Paola ^{[1
,2
]}

Valenti, Mario ^{[1
,2
]}

Pavia, Giulia ^{[1
,2
]}

Gargiulo, Luigi ^{[1
,2
]}

Narcisi, Alessandra ^{[1
]}

Costanzo, Antonio ^{[1
,2
]}

Borroni, Riccardo G. ^{[1
,2
]}

机构：

[1] Humanitas Univ, Dept Biomed Sci, Pieve Emanuele, MI, Italy

[2] Humanitas Clin & Res Ctr IRCCS, Dermatol, Rozzano, MI, Italy

来源：

INTERNATIONAL JOURNAL OF DERMATOLOGY | 2020年 / 59卷 / 08期

关键词：

D O I：

10.1111/ijd.15008

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：E267 / E268

页数：2

共 5 条

[1]

[Anonymous], 2020, TREATMENT GUIDELINE

[2]

Chinese Trial Clinical Registry, RAND OP LAB CONTR TR

[3] Should biologics for psoriasis be interrupted in the era of COVID-19? [J].

Lebwohl, Mark ;

Rivera-Oyola, Ryan ;

Murrell, Dedee F. .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 82 (05) :1217-1218

[4] Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? [J].

Liu, Bingwen ;

Li, Min ;

Zhou, Zhiguang ;

Guan, Xuan ;

Xiang, Yufei .

JOURNAL OF AUTOIMMUNITY, 2020, 111

[5] MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile [J].

Mahallawi, Waleed H. ;

Khabour, Omar F. ;

Zhang, Qibo ;

Makhdoum, Hatim M. ;

Suliman, Bandar A. .

CYTOKINE, 2018, 104 :8-13

← 1 →